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tion and initiation of IL-2 transcription. The pathways
that bridge early and late events are unresolved, al-
though studies increasingly implicate PI 3-kinase. PIWhether due to the chronology of discovery, or the com-
3-kinase binding also implicates this receptor in a di-plexity of the system, an understanding of CD28 cosig-
verse number of functions that have not previously beennaling pathways is only beginning to catch up with our
attributed to CD28.understanding of its biology. Functional studies by nu-
merous laboratories have shown that binding of CD28
by its ligands CD80 (B7-1) or CD86 (B7-2/B70) decisively CD28 Signaling Pathways
determines the destiny of the T cell response (reviewed What is the nature of the intracellular cosignal(s) that
recently by Jenkins, 1994; Bluestone, 1995; Thompson, accounts for CD28 function? Initial studiesdistinguished
1995; Linsley, 1995). T cell responses require a nonanti- TCRz±CD3 signaling from CD28 signaling based on the
gen-driven cosignal provided by CD28 (and possibly strict dependency of the former on calcium and sensitiv-
other antigens), in addition to ligation of the T cell recep- ity to cyclosporin A (CsA). Two parts of CD28 signaling
tor z (TCRz)±CD3 complex with CD4±p56lck or CD8± were suggested, a calcium-dependent pathway with
p56lck. Indeed, TCR ligation without costimulation can characteristics similar to TCRz±CD3 signaling and a
result in functional inactivation, or anergy of T helper 1 pathway that is CD28 specific, calcium independent,
(Th1) cells (Jenkins, 1994). In most T cells, CD28 lowers and CsA resistant (see June et al., 1994). However, a
the threshold needed for activation and increases re- direct link between CD28 and an intracellular signaling
sponse longevity, effects linked to increased transcrip- pathway was first provided with the finding that CD28
tion and stability of lymphokine mRNAs, in particular could be phosphorylated and then bind to the lipid ki-
those encoding interleukin-2 (IL-2) and IL-4 (Fraser et al., nase, PI 3-kinase (Truitt et al., 1994; Prasad et al., 1994;
1991; Thompson, 1995). Consequently, CD28-deficient August and DuPont, 1994a). A phosphotyrosine-based
mice have markedly diminished T cell responses to cer- motif pYMNM is conserved between species (human,
tain antigens (Shahinian et al., 1993). Cosignals also mouse, rat, and chicken) and serves as a binding motif
amplify cytolytic responses in tumor and autoimmune for the Src homology domain 2 (SH2 domain) of PI
models (Chen et al., 1992; Townsend and Allison, 1993) 3-kinase (Figure 1). PI 3-kinase is a heterodimer, com-
and may control the differentiation of Th1 versus Th2 posed of a p85 adaptor subunit linked to a p110 catalytic
subsets (Kuchroo et al., 1995; Bluestone, 1995; Freeman domain that phosphorylates the D-3 position of the ino-
et al., 1995). As if this were not enough, CD28 also sitol ring of phosphatidylinositol, phosphatidylinositol
regulates expression of Bcl-xL (Boise et al., 1995), and 4-phosphate, and phosphatidylinositol 4,5 bisphos-
a variety of surface antigens such as CTLA-4, the high phate generating PI 3-P, PI 3,4-P2, and PI 3,4,5-P3, re-
affinity IL-2 receptor, and the CD40 ligand (CD40L), each spectively. The p85 adaptor chain has two SH2 domains,
of which is needed for successful progression of T cell each of which is formed by two a helices and intervening
responses. b-pleated sheets that form grooves that bind to a core
By contrast, the structurally related molecule CTLA-4 phosphotyrosine residue and adjacent residues within
negatively regulates T cell proliferation. Anti-CTLA-4 an- the pYMNM motif (Figure 2). Methionine residues deter-
tibodies inhibit TCR and TCR±CD28 triggered prolifera- mine the specificity of p85 SH2 domain binding (Song-
tion (Walunas et al., 1994), while T cells from CTLA-4 nega- yang et al., 1993). In this regard, the avidity of p85 SH2
tive mice are hyperresponsive to antigen and undergo binding to CD28 is comparable to that of growth factor
spontaneous proliferation that leads to extreme lymph- receptors such as the platelet-derived growth factor
adenopathy (Waterhouse et al., 1995; Tivol et al., 1995). receptor (PDGF-R) (Prasad et al., 1994). The C-terminal
The emerging picture points to an interplay of positive domain has 10-fold greater avidity than the N-terminal
and negative signals mediated by TCR±CD3, CD4/CD8± SH2 domain, and is thus likely to dominate in binding.
p56lck, CD28, and CTLA-4. TCRz±CD3 and CD4/CD8± CD28 ligation recruits PI 3-kinase (Prasad et al., 1994)
p56lck initiate a complex array of intracellular signals that and, as shown in earlier work, can generate D-3 lipids
have been reviewed extensively elsewhere (Weiss and (Ward et al., 1993).
Littman, 1994). By contrast, as outlined in this review, By binding to PI 3-kinase, CD28 anchors the enzyme
the proximal and distal events of CD28 signaling are to the inner face of the plasma membrane, where it
just beginning to be understood. Proximal events are can act on its target substrates. Various functions are
initiated by phosphorylation of CD28 at the cytoplasmic dependent on the kinase, including growth factor±
pTyr±Met±Asn±Met (pYMNM) motif, followed by recruit- induced mitogenesis, glucose uptake, intervesicular
ment of the signaling proteins phosphatidylinositol transport, cytoskeletal organization, receptor traffick-
ing, and apoptosis (Kapeller and Cantley, 1994). Two3-kinase (PI 3-kinase), growth factor receptor±bound
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Figure 1. Conservation Between Species of the CD28 Cytoplasmic
Domain
A comparison of the CD28 cytoplasmic domains of human, mice,
rat, and chicken reveals conserved features. The 41 aa cytoplasmic
domain of human, rat, and mouse CD28 possesses four tyrosine
residues, one of which is present within a phosphotyrosine-based
motif pYMNM (Y-191 from the start codon and Y-173 in the mature
human protein) that binds to the SH2 domains of PI 3-kinase and
GRB-2. The chicken CD28 has an additional four residues (three
C-terminal and an additional internal residue) not found in human,
mouse, or rat CD28. Two potential SH3 binding motifs (PXXP) are
not conserved.
of these, the regulation of mitogenesis and apoptosis,
overlap with functions that have been attributed to
CD28. Targets of the kinase are only partially known
and the subject of much investigation. PI 3,4-P2 and PI
3,4,5-P3 can activate the d, e, u, and z isoforms of the
serine/threonine kinase, protein kinase C (PKC) (Nakani-
shi et al., 1993; Kapeller and Cantley, 1994) and related
AKT (Franke et al., 1995). PI 3-kinase may also activate
and/or may be activated by the GTP-binding protein
Figure 2. CD28 Binds to Multiple Intracellular Signaling Proteinsp21ras (Hu et al., 1995; Rodriguez-Viciana et al., 1994).
(Top) The 41 aa cytoplasmic tail of CD28 binds to three intracellularFurther downstream, PI 3-kinase is required for activa-
signaling molecules: PI 3-kinase, ITK, and the signaling complex
tion of the rapamycin-sensitive serine/threonine kinase GRB-2±SOS. The SH2 domains of PI 3-kinase and GRB-2 bind to
S6 kinase (p70S6K) by PDGF-R, and for initiation of DNA the pYMNM motif, while the mechanism of ITK binding has yet
synthesis (Fantl et al., 1992; Blenis, 1993). to be established. Based on peptide binding, GRB-2 binds with 10-
to 100-fold lower avidity than PI 3-kinase.To complicate matters further, CD28 can bind to two
(Bottom) The p85 subunit of PI 3-kinase consists of an SH3 domain,other intracellular proteins. The CD28 pYMNM site also
two proline motifs, a Bcr homology region, two SH2 domains, andbinds to the GRB-2 SH2 domain of the GRB-2±Son of
an SH2 domain intervening region (SH2i). The p85 C-terminal domain
Sevenless (GRB-2±SOS) complex (Schneider et al., of PI 3-kinase binds with 10-fold greater avidity than its N-terminal
1995) (Figure 2). GRB-2 is an adaptor chain that consists SH2 domain, and is thus likely to dominate inbinding to the receptor.
of one SH2 and two SH3 domains. While the SH2 domain The two proline motifs can mediate binding to the SH3 domains of
Src kinases, while the SH2i region mediates binding to the PIbinds to phosphotyrosine-based motifs of surface re-
3-kinase catalytic subunit.ceptors, the SH3 domain binds to proline residues within
SOS. In other systems, the guanine nucleotideexchange
activity of SOS converts p21ras from an inactive GDP-
bound state to an active GTP-bound state. Whether a However, only a small percent of ITK has been reported
to be recruited by the receptor, and preliminary datasimilar situation exits for CD28 is unclear. Both GRB-2
and PI 3-kinase bind to the same site, although GRB-2 show that CD28-mediated IL-2 production may not be
impaired in ITK-deficient mice (Liao and Littman, 1995).binds with 10- to 100-fold lower avidity (10-fold lower
avidity than the N-terminal p85 SH2 domain and 100- Although the mechanism underlying the interaction has
yet to be established, binding can occur independentfold lower than the C-terminalSH2 domain). The arginine
(N) of the pYMNM motif dictates GRB-2 SH2 domain of the pYMNM motif (Cai et al., 1995). Whether subsets
of ITK-dependent and independent peripheral T cellsbinding. Whether the stoichiometry of GRB-2 binding is
sufficiently high to generate productive signals is uncer- exist, or whether ITK plays a role in another CD28-medi-
ated function is being investigated. By binding to multi-tain, although it may also bind directly to PI 3-kinase
(Wang et al., 1995). ple signaling molecules, CD28 could engage multiple
signaling cascades in T cells. Distinct signaling path-The issue of stoichiometry also exists in the case of
CD28 binding to ITK (August et al., 1994) (Figure 2). ways could in turn regulate the different functions attrib-
uted to this receptor.Nonreceptor tyrosine kinases interact with surface re-
ceptors as initially shown with CD4±p56lck (Rudd et al., Since the receptor needs to be phosphorylated to
bind to PI 3-kinase and GRB-2, an intracellular tyrosine1994). Similarly, ITK possesses a unique N terminus, a
SH3 and SH2 domain, and a kinase domain that shares kinase is needed to phosphorylate the site in order to
provide the conditions for SH2 domain binding. Unlikegreatest homology with the Tec family of kinases. Given
its restricted expression in T cells, ITK is an attractive growth factor receptors, CD28 lacks an intrinsic tyrosine
kinase domain. What, then, is the kinase that initiatescandidate for cosignaling. As expected, CD28 ligation
can recruit and activate the kinase (August et al., 1994). cosignaling by phosphorylating CD28? p56lck and p59fyn
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have been identified in expression studies as two ki- costimulate with TCRz±CD3 could nevertheless support
IL-2 production in the presence of PMA±ionomycinnases that phosphorylate CD28 and recruit PI 3-kinase
and GRB-2 to the receptor (Raab et al., 1995). Neither (CeÂ fai et al., 1996). Therefore, phorbol ester may bypass
the need for the kinase, perhaps by acting on down-ITK nor ZAP-70 were found to phosphorylate the recep-
tor. p56lck demonstrates a remarkable specificity for the stream targets of PI 3-kinase. In this regard, both D-3
lipids and PMA activate PKC. PI 3,4-P2/PI 3,4,5-P3 acti-pYMNM motif. Over 90%of phosphorylation isobserved
at this site, despite the presence of three other tyrosine vate the d, e, u, z isoforms, while PMA can activate of
the a, b, g, d, e isoforms. In addition to this, PMA isresidues in the cytoplasmic domain (see Figure 1). In
agreement with a role for this kinase, J.Cam-1, a p56lck- known to act pleiotropically by binding to cysteine-rich
diacylglycerol binding motifs within proteins such as thedeficient cell line, showed reduced CD28-mediated re-
sponses (Lu et al., 1994). haematopoetic proto-oncogene Vav, and by activating
downstream signaling molecules that are independentlyWhether the kinase that phosphorylates CD28 is pro-
vided by CD4±p56lck, CD8±p56lck, or TCR/CD3±p59fyn, or regulated by CD28. These targets include p21ras, MAPK,
and SAPK/JNK (see below).operates independently of these receptors is unclear.
Coprecipitation with CD28 has been reported in weak The use of different primary signals may also account
for the discrepancy in results obtained using the inhibitordetergents (Hutchcroft and Bierer, 1994; August and
DuPont, 1994b), although when contrasted with CD4± of PI 3-kinase, wortmannin. While wortmannin has gen-
erally been reported to inhibit anti-CD3 plus anti-CD28p56lck binding, the interaction occurs with very low level
of stoichiometry (Raab et al., 1995). Current evidence costimulation in peripheral T cells (Ward et al., 1995;
Ueda et al., 1995; Ghiotto-Ragueneau et al., 1996), itstrongly suggests that CD28 acts as an independent
signaling unit. CD28 ligation can independently recruit fails to inhibit IL-2 production using a regime of anti-
CD28 plus PMA±ionomycin (Lu et al., 1995; HutchcroftPI 3-kinase and GRB-2 (Truitt et al., 1994; Prasad et al.,
1994; Ghiotto-Ragueneau et al., 1996), and the interac- et al., 1995; Ueda et al., 1995; Truitt et al., 1995). Given
these differences, consideration should be given to thetion can be reconstituted without the need for TCR or
CD4 expression (Raab et al., 1995). appropriateness of PMA±ionomycin as a primary signal
and substitute for TCR ligation.
Individual T cells may also be wired differently and,
CD28 Regulation of IL-2 Production as a consequence, vary in their requirement for PI
A prime function of CD28 is up-regulation of IL-2 produc- 3-kinase. Although a bit of a gold standard in immuno-
tion. This results from effects on IL-2 promoter transcrip- logic research, Jurkatcells possess a number of unusual
tion and on mRNA stability. Although controversial, in- features. For example, CsA can uniquely inhibit SAPK
creasing evidence supports a role for PI 3-kinase in the or JNK activation in Jurkat cells, but not in primary cells,
regulation of this event. Mutation of the tyrosine within or most other cell lines. Further, unlike peripheral T cells,
the pYMNM motif was initially reported to block anti- IL-2 production in Jurkat cells is actually enhanced by
CD28-induced IL-2 production in a T cell hybridoma the presence of wortmannin (Ueda et al., 1995).
(Pages et al., 1994). To distinguish among the roles of Despite these differences, it is interesting that muta-
PI 3-kinase, GRB-2±SOS, and ITK in costimulation, the tion of other residues within the CD28 cytoplasmic tail
methionine in the plus 3 position of the pYMNM motif such as asparagine (N) within the pYMNM motif, an
was mutated and found to selectively disrupt PI 3-kinase adjacent aspartic acid (D) residue, and other tyrosine
binding without affecting the binding of GRB-2 or ITK residues, disrupts PMA±ionophore-driven costimulation
(Cai et al., 1995). Nevertheless, the same mutation inhib- (Crooks et al., 1995; Truitt et al., 1995) (see Figure 1).
ited IL-2 production in a system that was dependent on Each of these residues is conserved between species
TCRz±CD3 and CD28 ligation (Cai et al., 1995). Anti- (see Figure 1). Other information contained within CD28
CD3 was used at 1029 to 10213 M, concentrations that may therefore be linked to other signaling pathways.
approximate physiological ligand. Thus, p85 binding This might explain why another PI 3-kinase binding re-
and possibly the associated PI 3-kinase catalytic sub- ceptor CD19 failed to support IL-2 production in the
unit were implicated in costimulation. By contrast, ex- presence of phorbol ester±ionomycin (Crooks et al.,
pression of the CD28 pY-173 mutant in Jurkat cells did 1995). Involvement of PI 3-kinase does not exclude the
not block cosignaling induced by combinations of anti- possible requirement for other signaling molecules (i.e.,
CD28 plus ionomycin±phorbol ester (Truitt et al., 1995; GRB-2 or ITK?).
Crooks et al., 1995). Phorbol ester was found to partially Clearly, further studies areneeded onthe relative roles
dissociate PI 3-kinase binding without inhibiting costim- of signaling pathways on IL-2 transcription and on in-
ulation (Hutchcroft et al., 1995). creased stability of cytokine mRNA. The inhibitory ef-
What might be the basis for this apparent discrepancy fects of wortmannin could result from a blockage of a
in experimental results? Two obvious differences are specific CD28-related signal, or reflect a more general
apparent, namely the mode of primary stimulation and requirement for PI 3-kinase in the cellular machinery. At
the nature of the host cells used for transfection. CD28 a minimum, mutagenic studies in TCR±CD28 cosignal-
required PI 3-kinase in the study that used TCRz±CD3 ing system argue for a role of the p85 adaptor protein.
ligation as the primary signal, but not in the studies p85 binding may then implicate the catalytic PI 3-kinase
that used phorbol ester and ionomycin. In this regard, subunit, or possibly another effector protein. The p85
TCRz±CD3 and phorbol myristate acetate (PMA)± adaptor possesses two SH2 domains, a SH3 domain as
ionomycin signaling are almost certainly not equivalent. well as a breakpoint cluster gene (Bcr) homology region
with homology to a Rho±GTPase activating protein,In support of this, theCD28 pYMNM mutant that failed to
Immunity
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each of which could interact with other proteins (see
Figure 2, bottom). For example, the proline-rich motifs
can interact with SH3 domains of Src kinases (Rudd et
al., 1994), while the Bcr homology region may interact
with small G proteins cdc42 and Rac-1 (Zeng et al.,
1994).
Differential Signaling by CD80 and CD86
CD80 and CD86 have been reported to differentially
regulate lymphokine production and the appearance of
Th1 versus Th2 subsets (Kuchroo et al., 1995; Bluestone,
1995; Freeman et al., 1995). Signaling studies have yet
to provide a molecular basis for this difference. Both
ligands induce CD28 phosphorylation, PI 3-kinase re-
cruitment, and the production of D-3 lipids with similar
levels of efficacy (Ueda et al., 1995; Ghiotto-Ragueneau
et al., 1996; CeÂ fai et al., 1996). Further, the disruption
of PI 3-kinase binding blocks IL-2 production mediated
by both CD80 and CD86 (CeÂ fai et al., 1996). Other mech-
anisms are therefore likely to account for the differential
effects of these ligands on lymphokine production.
Figure 3. The MAPK, SAPK/JNK, and p38/HOG1 Signaling ModulesDownstream Pathways
p21rac, p21ras, or both, and cdc42 could initiate parallel signalingPotential downstream targets of CD28 signaling in-
cascades leading to the activation of MAPK, SAPK/JNK, and p38/
volves a complicated network of kinases that are sum- HOG-1. This is a blow-up of the intermediate steps (represented by
marized in Figure 3. Prominent amongst these are the broken lines) linking p21ras to MAPK and p21rac/cdc42 to SAPK/JNK
MAPK, SAPK/JNK, and p38/HOG-1 signaling modules. and p38/HOG1 seen in Figure 4. p21ras binds and activates the serine
kinase Raf-1 (and possibly MEKK1,2,3), which in turn phosphoacti-In brief, the cascade is initiated by the activation of a
vates MEK1,2, which in turn phosphoactivates the MAP kinasesGTP-binding protein such as p21ras, which activates a
(ERKs 1,2). Similarly, p21rac and cdc42 regulate PAKs as well asserine kinase such as Raf-1, which in turn continues the
MEKK1,2,3-SEK(MKK4)±SAPK/JNK or the MEKK?±MKK6
cascade by phosphoactivating the MEK1,2 kinases that (SEK,MKK3)±p38/HOG1 signaling modules, or both. MAPK and
then activate MAPK (ERKs 1,2). Parallel pathways in- SAPK are activated by the dual phosphorylation of tyrosine and
volving p21rac and cdc42 and their regulation of the threonine residues. MAPK phosphatase-1 (MKP-1) dephos-
phorylates and inactivates MAPK. CD28 markedly activates theSAPK/JNK and p38/HOG-1 kinase modules also exist
SAPK/JNK pathway in the presence of TCR±CD3 ligation. By con-(see Figure 3). It is important to note that the MAPK and
trast, both TCR and CD28 activate MAPK, although TCR is moreSAPK pathways are differentially responsive to various
efficient. c-Jun is the preferred target of SAP/JNK, while ATF2 and
stimuli. Mitogens tend to activate the MAPK pathway, to a lessor extent c-Jun-P serve as targets for p38/HOG1. The tran-
while stress-related stimuli such as tumor necrosis fac- scription factor ELK1 is the target of MAPK. ELK1 regulates the
tor-a (TNFa) and ultraviolet irradiation preferentially expression of genes such as fos, whereas ATF2 is a cyclic AMP
responsive element binding protein. Abbreviations include p21-acti-stimulate the SAPK pathway (Kyriakis et al., 1994).
vated kinase (PAK); mitogen activated kinase kinase 1,2,3 or 6Interestingly, this distinction can be extended to sig-
(MKK1,2,3 or 6); mitogen-activated kinase (MAPK); the stress-acti-nals generated by the TCRz±CD3 and CD28 receptors.
vated protein kinase/c-jun amino terminal kinase (SAPK/JNK); mito-
Ironically, CD28 ligation induces a stress-related re- gen-activated kinase p38 (p38); activating transcription factor 2
sponseby activatingthe SAPK/JNK pathway in thepres- (ATF2).
ence of TCRz±CD3 ligation (Su et al., 1994). TCRz±CD3
ligation alone preferentially activates the MAPK (ERKs)
pathway (Su et al., 1994). SAPK/JNK activation corre- 1995), although some NF-kB family members may also
bind (Lai et al., 1995). Each NF-AT±AP-1 composite bind-lates well with IL-2 transcription, most probably due
to its ability to phosphorylate c-jun and increase the ing site is needed for IL-2 gene transcription. Therefore,
in a minimal model, TCRz/CD3±CD4 signaling throughtranscriptional activity of AP-1 (Jun±Fos) complexes
within the IL-2 promoter (see Figure 4). Consistent with the calcineurin±cyclophilin pathway would lead to NF-
AT entry into the nucleus, while CD28 would contributethis notion, CD28 ligation appears necessary for AP-1
activity in transgenic mice carrying a reporter gene (Rin- AP-1 complexes with enhance AP-1 transcriptional ac-
tivity. NF-AT and AP-1 form complexes that then bindcon and Flavell, 1994). Although unexamined, the p38/
HOG-1 pathway is also predicted to influence transcrip- to the promoter.
Although attractive, other levels of complexity are cer-tion by c-jun phosphorylation, although it phosphory-
lates this substrate less efficiently than SAPK/JNK. The tain to impinge on this network. Crosstalk between com-
ponents of the serine kinase modules would ensureIL-2 promoter is composed of two Oct-1 binding sites,
four adjacent AP-1 and nuclear factor of activated T some cross-regulation. For example, oncogenic forms
of Ras and Raf-1 can activate IL-2 transcription (Raytercells (NF-AT) binding sites, an additional NF-AT site,
and a NF-kB binding site. The CD28 response element et al., 1992; Baldari et al., 1993), while constitutively
active PI 3-kinase activates Fos transcription (Hu et al.,(CD28RE) is AP-1±NF-AT binding site (Rooney et al.,
Review
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Figure 4. Model of the Potential Pathways
Leading from CD28 to the Regulation of IL-2
Transcription
CD28 regulation of the MAPK, SAPK/JNK,
and p38/HOG-1 signaling modules. CD28 li-
gation has been reported to activate p21ras,
MAPK, and SAPK/JNK. In a minimal model,
TCRz/CD3±CD4 could contribute NF-AT,
while CD28 could provide enhanced AP-1
transcriptional activity though c-jun phos-
phorylation. TCR±CD3 and CD28 signals
would thus converge in the nucleus with the
formation of the NF-AT±AP-1 complexes
needed for IL-2 transcription. The IL-2 pro-
moter is composed of two Oct-1 binding
sites, four adjacent AP-1 and NF-AT binding
sites, an additional NF-AT site, and a NF-kB
binding site. Each NF-AT±AP-1 composite
binding site is needed for IL-2 gene transcrip-
tion. CD28 regulation of the MEKK1±SEK±
SAPK/JNK module is a potential link to IL-2
transcription. The events that bridge the
CD28 early events with the activation of the
SAPK/JNK pathway are unresolved, although
may involve PI 3-kinase. PI 3-kinase could
regulate SAPK(JNK) kinases by the activation
of GTP-binding proteins p21ras, p21rac, or
cdc42, through the generation of D-3 lip-
ids and their phosphoactivation of MAPK,
SAPK(JNK), and p38(HOG-1) or via the phos-
phorylation of substrates such as Vav. AKT
regulation by D-3 lipids may be linked to the
activation of p70S6K and DNA synthesis. The
intermediate steps (represented by broken
lines) linking p21ras to MAPK and p21rac/cdc42
to SAPK/JNK and p38/HOG1 are represented
in detail in Figure 3.
1995). In terms of the components needed for the IL-2 constitutively active form (Genot et al., 1995). In this
regard, ceramide, a product of the sphingomyelin path-promoter, TCRz±CD3 ligation can induce NF-AT, jun
(c-jun, JunB) and Fos (c-fos, FosB) expression, while way, may synergize with the cascade through its activa-
tion of PKC (Chan and Ochi, 1995; Boucher et al., 1995).CD28 selectively induces Jun expression (Chatta et al.,
1994). CD28 signaling may also reduce IkB expression In a third scenario, CD28 may generate signals by phos-
phorylation of substrates at 110, 95, 68, and 36 kDa andand facilitate translocation of Rel/NF-kB to the nucleus
(Bryan et al., 1994; Lai and Tan, 1994). their regulation of downstream targets (Lu et al., 1994;
Nunes et al., 1994). Vav (95 kDa) and Lnk (p36) are ofGiven this model of downstream events, how might
CD28 binding to upstream signaling molecules be linked particular note, given their binding to GRB-2±SOS, and
its potential influence on p21ras. This in turn may beto downstream signaling? At this point, one can only
speculate. One possibility is that PI 3-kinase activates connected with GRB-2 binding to the receptor.
Some question exists whether antibody to CD28 canp21rac or related GTP binding proteins, which in turn
regulate the serine kinase signaling modules. In support accurately mimic natural ligand. This is a valid concern
that may relate to the concentration of ligand, differ-of this, constitutively active PI 3-kinase has been re-
ported to activate p21ras (Hu et al., 1995). In a second ences in the degree of cross-linking, and the site of
binding. Most activation studies use antibody at con-scenario, the PI 3,4-P2 and PI 3,4,5-P3 lipids produced
by PI 3-kinase could activate the z, d, e , h isoforms of centrations that are 4±6 orders of magnitude greater
than natural ligand. While both induce some tyrosinePKC (see Figure 4). Some activation of the PI 3-kinase
may be induced by GTP-binding proteins that bind and phosphorylation of substrates (for example, Vav), anti-
body has generally been used to demonstrate p21rasactivate the enzyme (Zeng et al., 1994; Rodriguez-Vici-
ana et al., 1994). Once activated, the different PKC iso- (Nunes et al., 1994), MAPK (August and DuPont, 1994a;
Nunes et al., 1994), and SAPK/JNK activation (Su et al.,forms could transactivate MAPK, SAPK, or p38. In sup-
port of this, PKCz has been reported to phosphoactivate 1994). In one report, CD80 was unable to mimic the
effect of anti-CD28 in the activation of p21ras (Nunes etMEK and MAPK, but not SAPK (Berra et al., 1995). A
key question is whether other PKC isoforms regulate al., 1994). Whether this discrepancy involves an intrinsic
difference in ligand binding, or is simply related to aother branches of the serine/threonine kinase cascade?
Of particular interest is the PKCe isoform, which can lower receptor occupancy and sensitivity of cellular
assays, is uncertain.activate AP-1 and NF-AT activity when expressed in
Immunity
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August, A., and DuPont, B. (1994b). Activation of the src kinase lckA key issue in assessing CD28 cosignaling pathways
following CD28 crosslinking in the Jurkat leukemic cell line. Bio-is the degree to which they overlap with TCRz/CD3±
chem. Biophys. Res. Commun. 199, 1466±1473.CD4±p56lck signals. TCRz±CD3 signaling is more com-
August, A., Gibson, S., Kawakami, Y., Kawakami, T., Mills, G.B.,plex, employing additional components that are not
and Dupont, B. (1994). CD28 is associated with and induces the
engaged in costimulation (such as ZAP-70, cyclophilin± immediate tyrosine phosphorylation and activation of the Tec family
calcineurin). Nevertheless, to different extents, both re- kinase ITK/EMT in the human Jurkat leukemic T cell line. Proc. Natl.
ceptors share targets such as p21ras, MAPK, SAPK/JNK, Acad. Sci. USA 91, 9347±9351.
Vav±p36 and can generate D-3 phosphoinositides. For Baldari, C.T., Heguy, A., and Telford, J.L. (1993). Ras protein activity
example, while both receptors activate MAPK, TCRz± is essential for T cell receptor signal transduction. J. Biol. Chem.
268, 2693±2698.CD3 provides a more potent signal. Conversely, while
Berra, E., Diaz-Meco, M.T., Lozano, J., Frutos, S., Municio, M.M.,p59fyn and p56lck use their SH3 domains to recruit PI
Sanchez, P., Sanz, L., and Moscat, J. (1995). Evidence for a role of3-kinase to the TCRz±CD3 and CD4 receptors, CD28
MEK and MAPK during signal transduction by protein kinase Cz.binds several-fold more enzyme than TCR/CD3±CD4
EMBO J. 14, 6157±6163.
(Rudd et al., 1994). In this way, CD28 may adjust the
Blenis, J. (1993). Signal transduction via the MAP kinases: proceedthreshold of signaling by supplementing suboptimal sig-
at your own risk. Proc. Natl. Acad. Sci. USA 90, 5889±5892.
nals generated by the TCRz±CD3 and CD4/CD8±p56lck.
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